Literature DB >> 8977232

Physical and functional interactions between Stat5 and the tyrosine-phosphorylated receptors for erythropoietin and interleukin-3.

H Chin1, N Nakamura, R Kamiyama, N Miyasaka, J N Ihle, O Miura.   

Abstract

Erythropoietin (Epo) and interleukin-3 (IL-3) stimulate activation of the Jak2 tyrosine kinase and induce tyrosine phosphorylation and activation of Stat5. In the present study, we have shown that Epo or IL-3 stimulation induces binding of Stat5 to the tyrosine-phosphorylated Epo receptor (EpoR) or IL-3 receptor beta subunit (betaIL3), respectively, in IL-3-dependent 32D cells expressing the EpoR. The binding of Stat5 to these cytokine receptors was shown to be rapid and transient, occurring within 1 minute of stimulation of cells and significantly decreasing after 5 minutes of cell treatment. In vivo binding experiments in COS cells showed that binding of Stat5 to the EpoR was mediated through the Stat5 Src homology 2 (SH2) domain. In vitro binding studies further showed that Stat5, but not other Stats examined, bound specifically to tyrosine-phosphorylated recombinant EpoR fusion proteins. In these in vivo and in vitro binding studies, Stat5 bound, albeit to a lesser degree, to truncated EpoR mutants in which all the intracellular tyrosines except Y-343 were removed. Furthermore, EpoR-derived synthetic phosphotyrosine peptides corresponding to Y-343, Y-401, Y-431, and Y-479 inhibited the in vitro binding of Stat5. When expressed in 32D cells, a mutant EpoR in which all the intracellular tyrosines were removed by carboxy-terminal truncation showed a significantly impaired ability to induce tyrosine phosphorylation of Stat5, particularly at low concentrations of Epo, but exhibited an increased sensitivity to Epo for growth signaling as compared with the wild-type EpoR. These results indicate that Stat5 specifically and transiently binds to the EpoR through the interaction between the Stat5 SH2 domain and specific phosphorylated tyrosines, including Y-343, in the EpoR cytoplasmic domain. It was implied that betaIL3 may also have similar Stat5 docking sites. The Stat5 docking sites in the EpoR were shown to facilitate specific activation of Stat5, which, however, may not be required for the EpoR-mediated growth signaling.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977232

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Cytokine signaling to the cell cycle.

Authors:  Frederick W Quelle
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 2.  Cytokine receptor splice variants in hematologic diseases.

Authors:  Borwyn Wang; Hrishikesh Mehta
Journal:  Cytokine       Date:  2019-12-06       Impact factor: 3.861

3.  Design of conditionally active STATs: insights into STAT activation and gene regulatory function.

Authors:  L H Milocco; J A Haslam; J Rosen; H M Seidel
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

4.  STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.

Authors:  Megumi Funakoshi-Tago; Kenji Tago; Miyuki Abe; Yoshiko Sonoda; Tadashi Kasahara
Journal:  J Biol Chem       Date:  2009-12-22       Impact factor: 5.157

5.  Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.

Authors:  Fumihito Ueda; Kenji Tago; Hiroomi Tamura; Megumi Funakoshi-Tago
Journal:  J Biol Chem       Date:  2016-12-20       Impact factor: 5.157

6.  Thermal injury of the skin induces G-CSF-dependent attenuation of EPO-mediated STAT signaling and erythroid differentiation arrest in mice.

Authors:  John G Noel; Benjamin J Ramser; Jose A Cancelas; Francis X McCormack; Jason C Gardner
Journal:  Exp Hematol       Date:  2017-09-01       Impact factor: 3.084

7.  Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.

Authors:  Geza Acs; Paul J Zhang; Cindy M McGrath; Peter Acs; John McBroom; Ahmed Mohyeldin; Suzhen Liu; Huasheng Lu; Ajay Verma
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

8.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro.

Authors:  J R Grandis; S D Drenning; A Chakraborty; M Y Zhou; Q Zeng; A S Pitt; D J Tweardy
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

9.  AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells.

Authors:  S M Jacobs-Helber; A Wickrema; M J Birrer; S T Sawyer
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

10.  BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor.

Authors:  S Okabe; T Fukuda; K Ishibashi; S Kojima; S Okada; M Hatano; M Ebara; H Saisho; T Tokuhisa
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.